Aso M, Toi Y, Sugisaka J, et al. - In view of the frequent occurrence of immune-related adverse events, such as skin reactions, in relation to treatment with anti-programmed cell death 1 antibody, and the link of skin reactions with clinical efficacy in melanoma, researchers investigated potential correlations of skin reactions with clinical effectiveness and clinical predictors of the development of skin reactions in patients with advanced non-small cell lung cancer managed with nivolumab or pembrolizumab monotherapy at Sendai Kousei Hospital (n = 155), via this retrospective survey. With a median time to onset of 6.4 weeks, skin reactions were detected in 51 patients. Patients with skin reactions had a significantly higher overall response rate in the 6-week landmark analysis, and a significant link of skin reactions with increased progression-free survival was also revealed. In multivariate analysis, the preexisting rheumatoid factor was identified as an independent predictor of skin reactions. In this patient population managed with nivolumab/pembrolizumab, the possible benefits of skin reactions were suggested.